- Impact Factor: 2.876*
- Indexed In: Clarivate Analytics: Social Science Index Expanded (Web of Science), PubMed Central, Medline, SCOPUS, EMBASE, Index Medicus, and the DOAJ
- Fast and double-blind peer review by dedicated Associate Editors and Editorial Board Members
- Global visibility due to international audience of multidisciplinary researchers
- Publication is subject to payment of an article processing charge (APC)
- Submit here
Technology in Cancer Research and Treatment (TCRT) is an open access, peer-reviewed journal which focuses on developments in the prevention, diagnosis, treatment, and monitoring of cancer. Please see the Aims and Scope tab for further information.
This journal is a member of the Committee on Publication Ethics (COPE).
Submit your manuscript at https://mc.manuscriptcentral.com/tcrt.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.
The article processing charge (APC) for this journal is currently 2400 USD (+VAT where applicable*).
As part of the manuscript submission process, authors can request a full Technical Edit of their manuscript to take place after peer review. For articles opting to receive a Technical Edit, the APC is currently 3600 USD (+VAT where applicable*).
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Please direct any queries to firstname.lastname@example.org.
Why Publish Open Access with TCRT
- Visibility and Impact: Anyone anywhere in the world can read, use and cite your research
- Rigorous Standards: Double-blind peer review policy
- Speed: Less than 2 months from submission to first decision and 4 weeks from acceptance to online publication
- Flexibility: No page limits or page charges, and authors can publish full data sets, figures, tables, etc
- Copyright: Authors retain copyright under a Creative Commons License
- Contact the Editor: email@example.com
This journal changed its publication mode from subscription to open access in 2016.
Technology in Cancer Research and Treatment (TCRT) is a JCR-ranked, broad-scoped, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.
Article Types and Topics of Interest
TCRT welcomes original research (both basic and clinical studies), reviews, and commentaries. We encourage submissions relating to advances in the following areas:
|Preventative or Diagnostic
Treatment or Monitoring
Click here to see a selection of the latest papers published in TCRT
|Jennifer K. Lovick, PhD||SAGE Publishing, Thousand Oaks, CA USA|
|Mukti H. Sarma, PhD||University at Albany - SUNY, New York, USA|
|Applonia Rose, PhD||SAGE Publishing, Thousand Oaks, CA USA|
|Priyanka Katyal, PhD||SAGE Publications, New Delhi, India|
|Pooja Sharma, MTech||SAGE Publications, Dehradun, India|
|Jake Bobbe, MA||SAGE Publications Ltd, UK|
|Genggeng Qin, MD, PhD||Nanfang Hospital, Southern Medical University, China|
|Masayuki Tsuneki, DMD, PhD||Medmain Research, Medmain Inc., Japan|
|Yu-Dong Zhang, PhD||University of Leicester, UK|
|J.T. Efird, PhD||VA - Cooperative Studies Program Coordinating Center, Boston, MA, USA, & Case Western Reserve University School School of Medicine, Cleveland, OH, USA|
|Arpit Tandon, MS||Sciome LLC, USA|
|Yanfeng Zhang, PhD||University Of Texas Southwest Medical Center, USA|
|Jian-Guo Zhou, MD||Universitätsklinikum Erlangen, Germany|
|Liang Qiao, MD, PhD||The University of Sydney, Australia|
|Jiaolin Bao, PhD||Hainan University, China|
|A. Emre Eskazan, MD||Istanbul University-Cerrahpasa, Istanbul, Turkey|
|Alessandro Rizzo, MD||IRCCS Bari Hospital, Italy|
|Timo L.M. Ten Hagen, PhD||Erasmus MC, Netherlands|
|Yoed Rabin, DSc||Carnegie Mellon University, Pittsburgh, USA|
|Maria Rosaria De Miglio, MD, PhD||University of Sassari, Italy|
|Dong Wang, PhD||Chengdu University of Traditional Chinese Medicine, China|
|Satiro De Oliveira, MD||David Geffen School of Medicine at UCLA, Los Angeles, CA, USA|
|Xiaotao Jiang, PhD||Southern Medical University, China|
|Sandeep Kumar, PhD||The University of Illinois at Chicago, USA|
|Qian Xiao, PhD||Yale School of Medicine, USA|
|Xiance Jin, PhD||The First Affiliated Hospital of Wenzhou Medical University, China|
|Kujtim Latifi, PhD||Moffitt Cancer Center, Tampa, FL USA|
|Qianqian Ni, PhD||Medical School of Nanjing University, China|
|Paolo Spinnato, MD||IRCCS Istituto Ortopedico Rizzoli, Italy|
|Ioannis Tsougos, MSc, PhD||University of Thessaly, Greece|
|Yu-Dong Xiao, MD, PhD||Second Xiangya Hospital, Central South University, China|
|Yidong Yang, PhD, DABR||University of Science and Technology of China, China|
|Xin Zhang, PhD||Boston University School of Medicine, Boston, MA, USA|
|Raghavendiran Boopathy PhD, DABR||Oregon Health and Science University, USA|
|Fayçal Kharfi, DSc||Ferhat Abbas Setif1 University, Algeria|
|Guang (George) Li, PhD||Memorial Sloan Kettering Cancer Center, USA|
|Yixiang Liao, PhD||Rush University Medical Center, USA|
|Nariman Nezami, MD||University of Maryland School of Medicine, USA|
|Xinye Ni, PhD||Nanjing Medical University, China|
|Zhilei L. Shen, PhD, DABR||University of Southern California, USA|
|Dandan Zheng, PhD||University of Nebraska Medical Center, USA|
|Zhong Feng Gao, PhD||Qilu University of Technology (Shandong Academy of Sciences)|
|Qingyu Lin, PhD||Sichuan University, China|
|Chuanbin Mao, PhD||University of Oklahoma, USA|
|Caroline Palm Apergi, PhD||Karolinska Institutet, Sweden|
|Tin Wui Wong, PhD||Universiti Teknologi MARA, Malaysia|
|Shigao Huang, PhD||Xijing Hospital, Air Force Medical University, China|
|Robert Griffin, PhD||University of Arkansas, Little Rock|
|Francesco Giurazza, MD, PhD, EBIR||Cardarelli Hospital of Naples, Italy|
|Seok Ho Lee, MD, PhD||Gachon University Gil Medical Center, South Korea|
|Xi Yang, MD, PhD||Fudan University Shanghai Cancer Center, China|
|Baoshe Zhang, PhD||University of Maryland School of Medicine, USA|
|Davide Campobasso, MD||University Hospital of Parma, Italy|
|Chih-Yen Chien, MD, FACS||Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Taiwan|
|Fabio Cofano, MD||University of Torino, Italy|
|Bo Deng, MD, PhD||Daping Hospital, Army Medical University, China|
|Gianluca Franceschini, PhD||Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy|
|Cheng-Maw Ho, MD, PhD||National Taiwan University Hospital and College of Medicine, Taiwan|
|Wenjun Mao, MD, PhD||The Affiliated Wuxi People's Hospital of Nanjing Medical University, China|
|Vladimir Neychev, MD, PhD||University of Central Florida, USA|
|Antonio Sterpetti, MD||Sapienza University of Rome, Italy|
|Truls E. Bjerklund Johansen, PhD||Oslo University Hospital, Norway|
|Maja Cemazar, PhD||Institute of Oncology, Ljubljana, Slovenia|
|Shiekh Tanveer Ahmad, MS, PhD||St. Jude Children’s Research Hospital, USA|
|Mumtaz Anwar, PhD||University of Illinois at Chicago, USA|
|Natarajan Aravindan, PhD||University of Oklahoma Health Sciences Center, USA|
|Marc D. Basson, MD, PhD||University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND, USA|
|Rosario Caltabiano, MD||University of Catania, Italy|
|Wei Cao, MD, PhD, DDS||National Clinical Research Center for Oral Disease, China|
|Parthasarathy Chandrakesan, PhD||University of Oklahoma Health Sciences Center, USA|
|Shengxi Chen, PhD||Arizona State University, USA|
|Hongwei Cheng||Xiamen University, Xiamen, Fujian, China|
|William Cho, PhD||Queen Elizabeth Hospital, China|
|Mengyuan Dai, MD, PhD||Wuhan University, China|
|Semra Demokan, PhD||Istanbul University, Turkey|
|Rohit Gundamaraju, PhD||University of Tasmania, Australia|
|Gamze Guney Eskiler, PhD||Sakarya University, Turkey|
|Wei Han, PhD||Medical School of Nanjing University, China|
|Lukas J. A. C. Hawinkels, PhD||Leiden University Medical Center, The Netherlands|
|Daniel Wai-Hung Ho, PhD||University of Hong Kong, China|
|Md. Wasim Khan, PhD||University of Illinois at Chicago, USA|
|Nameer Kirma, PhD||University of Texas Health San Antonio, USA|
|Fatih Kose, PhD||Baskent University, Turkey|
|Mafalda Laranjo, PhD||University of Coimbra, Portugal|
|Yun-Han Lee, PhD||Keimyung University, South Korea|
|Xiaoyang Li MD, PhD||National Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China|
|Huanliang Liu, MD, PhD||The Sixth Affiliated Hospital Sun Yat-sen University, China|
|Zukile Mbita, PhD||University of Limpopo, South Africa|
|Meysam Moghbeli, PhD||Masshad University Of Medical Sciences, Iran|
|Jayakumar Nair, PhD||National Cancer Institute, USA|
|Mohamed M. Omran, PhD||Helwan University, Egypt|
|Dulal Panda, PhD||National Institute of Pharmaceutical Education and Research, Mohali, India|
|Manash K. Paul, PhD||University of California-Los Angeles, USA|
|Judit E Pongracz, PhD||University of Pecs, Hungary|
|Chandra Prakash Prasad, PhD||All India Institute of Medical Sciences, New Delhi, India|
|Wenan Qiang, MD, PhD||Northwestern University, USA|
|Yiqing Tian, MM, MD||Xinyi People's Hospital, China|
|Marco Tucci, MD, PhD||University of Bari, Italy|
|Omkara L. Veeranki, DVM, PhD||The University of Texas MD Anderson Cancer Center, USA|
|Marco A. Velasco-Velazquez, PhD||National Autonomous University of Mexico, Mexico|
|Dong Wang, PhD||Chengdu University of Traditional Chinese Medicine, China|
|Liang Wang, MD, PhD||China Medical University, China|
|Weiren Luo, MD, PhD||Southern University of Science and Technology, China|
|Nathaniel Weygant, PhD||Fujian University of Traditional Chinese Medicine, China|
|Zhijie Xu, MD, PhD||Xiangya Hospital, Central South University, China|
|Yuanliang Yan, PhD||Xiangya Hospital, Central South University, China|
|Dong-Hua Yang, MD, PhD||St. Johns University, USA|
|Yuhan Yang, MD||West China Hospital, Sichuan University, China|
|Hou-Qun Ying, PhD||The Second Affiliated Hospital of Nanchang University, China|
|Abass Alavi, MD||Perelman School of Medicine, University of Pennsylvania, USA|
|Robert Alfano, PhD||The City College Of New York, CUNY|
|Filippo Alongi, MD||Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy|
|Mario Ammirati, MD, MBA||St. Rita Medical Center/Mercy Health, Lima OH, USA|
|Jianfeng Bao||Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, China|
|John G. Baust, PhD||State University of New York, Binghamton, USA|
|Stewart Becker, PhD||New York University, Langone Medical Center, USA|
|Dzevad Belkic, PhD||Karolinska Institute, Stockholm, Sweden|
|Karen Belkic, MD, PhD||Claremont Graduate University, California, USA|
|Seetharam Bhat, MCh||Global Robotics Institute, Florida, USA|
|Max K. Bulsara, PhD||The University of Notre Dame, Australia|
|George A. Calin, MD, PhD||The University of Texas M.D. Anderson Cancer Center, Houston, USA|
|Jeffrey J. Chalmers, PhD||Ohio State University, Columbus, USA|
|Yong-zi Chen, PhD||Tianjin Medical University Cancer Institute and Hospital, China|
|Gregory Czarnota, MD, PhD||Sunnybrook Research Institute, University of Toronto, Canada|
|Hadassa Degani, PhD||The Weizmann Institute of Science, Israel|
|Ayman El-Baz, PhD||University of Louisville, Kentucky, USA|
|Adel K. El-Naggar, MD, PhD||The University of Texas, MD Anderson Cancer Center, Houston, TX, USA|
|Ammad A. Farooqi, PhD||Institute of Biomedical and Genetic Engineering (IBGE), Pakistan|
|Antonella Fogliata, PhD||IRCCS Istituto Clinico Humanitas, Italy|
|Andrew A. Gage, MD||State University of New York, Buffalo, USA|
|Roberto Gambari, PhD||University of Ferrara, Italy|
|A.H. Gandjbakhche, PhD||National Institutes of Health, Bethesda, Maryland, USA|
|Uwe Haberkorn, PhD||University of Heidelberg, Germany|
|Garret M. Hampton, PhD||Genomics Institute of the Novartis Research Foundation, California, USA|
|Samir Hanash, MD, PhD||The University of Texas MD Anderson Cancer Center, USA|
|Richard Heller, PhD||Old Dominion University, Virginia|
|Dwight Heron, MD||University of Pittsburgh Cancer Institute, Pennsylvania, USA|
|David Isaacson, PhD||Rensselaer Polytechnic Institute, New York|
|Samie R. Jaffrey, MD, PhD||Cornell University, New York, USA|
|Kewal K. Jain, MD||Pharmabiotech, Switzerland|
|Wei-Lin Jin, MD||The First Hospital of Lanzhou University, China|
|Tomas Kron, PhD||Peter MacCallum Cancer Center, Australia|
|David Larson, MD, PhD||University of California, San Francisco, USA|
|Frederick Locke, MD||Moffitt Cancer Center, Florida|
|Jay Loeffler, MD, FACR, FASTRO||Massachusetts General Hospital, Boston, USA|
|Kenneth Lundstrom, PhD||PanTherapeutics, Switzerland|
|Lijun Ma, PhD||USC Keck School of Medicine, USA|
|Paola Maycotte, PhD||Centro de Investigación Biomédica de Oriente, Puebla, Mexico|
|William M. Mendenhall, MD||Shands Cancer Center, Florida, USA|
|Arlan H. Mintz, MD||University of Pittsburgh, Pennsylvania, USA|
|Filippo Molinari, PhD||Politecnico di Torino, Italy|
|Sten Myrehaug, PhD||Sunnybrook Health Sciences Centre, University of Toronto, Canada|
|Subir Nag, MD||Kaiser Permanente, Santa Clara, California, USA|
|Yin Kwee Ng, PhD||Nanyang Technological University, Singapore|
|Dattatreyudu Nori, MD, FACR||New York Presbyterian Hospital, USA|
|Yong Peng, PhD||Sichuan University, China|
|Dilini Pinnaduwage, PhD||St. Joseph’s Hospital and Medical Center, USA|
|Tomasz Piotrowski, PhD, DSc||Greater Poland Cancer Center, Poznan, Poland|
|Veena N. Rao, PhD||Morehouse School of Medicine, Atlanta, GA, USA|
|William F. Regine, MD||University of Maryland, Baltimore, USA|
|Thomas Reid, MD||National Cancer Institute, Bethesda, Maryland, USA|
|David Roberge, MD||McGill University, Canada|
|Berkman Sahiner, PhD||University of Michigan, Ann Arbor, USA|
|Olga Savvidou, MD||Athens University Medical School, Greece|
|Daniel Scherman, PhD||INSERM, France|
|Reinhard Schulte, MD||Loma Linda University, California, USA|
|Eva M. Sevick-Muraca, PhD||University of Texas Health Sciences Center, Houston, USA|
|Richard Simpson, PhD||La Trobe University, Australia|
|Keshav Singh, PhD||University of Alabama, Birmingham, USA|
|Hany Soliman, MD, FRCPC||Sunnybrook Research Institute, University of Toronto, Canada|
|Luis Souhami, MD||McGill University, Canada|
|Gunnar Steineck, MD, PhD||University of Gothenburg, Gothenburg, Sweden|
|H. Cuneyt Ulutin, MD, PhD||Yeni Yuzyil University, Turkey|
|Xiaoying Wang, PhD||Tianjin University of Traditional Chinese Medicine, Tianjin, China|
|Yihong Wang, MD, PhD||Brown University, USA|
|James S. Welsh, MS, MD, FARCO||Stritch School of Medicine Loyola University- Chicago, USA|
|Andrew Wroe, PhD, DABR||Loma Linda University Medical Center, USA|
|Sue S. Yom, MD, PhD||University of California, San Francisco, USA|
|Cedric Yu, PhD||University of Maryland, Baltimore, USA|
|Wenwei Yu, PhD||Chiba University, Japan|
|Baohong Yuan, PhD||University of Texas at Arlington, USA|
|Ning J. Yue, PhD, FAAPM||Rutgers Robert Wood Johnson Medical School, New Jersey, USA|
|Marco Zaider, PhD||Memorial Sloan Kettering Cancer Center, New York, USA|
|Nikolai Zhelev, PhD, CBiol, EurProBiol||The University of Dundee, UK|
|Abdullah Faruk Zorlu, MD||Hacettepe University, Turkey|
|Pankaj Ahluwalia, PhD||Augusta University, USA|
|Orouba Almilaji, PhD||London School of Hygeine and Tropical Medicine, UK|
|Bahauddeen Alrfaei, PhD||King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia|
|Richard Amos, MSc, CSci, FIPEM||University College London, UK|
|Eman A. El-maadawy, PhD||Universirty of Sadat City, Egypt|
|Francisco Arenas-Huertero, PhD||Hospital Infantil de México Federico Gómez, Mexico|
|Arya Ashok, PhD||Tempus Labs Inc, Chicago, USA|
|Mohammed A Azab, MD||Boise State University, USA|
|Doaa Attia, MD||Cleveland Clinic Foundation, USA|
|Nevim Aygun, PhD||Ege University, Turkey|
|Ganesh Kumar Barik, MSc||National Centre for Cell Science, India|
|Saikat Bhattacharya, PhD||Stowers Institute for Medical Research, USA|
|Jan Bienkiewicz, MD, PhD||Polish Mother's Memorial Hospital Research Institute, Poland|
|Amany Belal, PhD||Beni-Suef University, Egypt|
|Nrusingh C. Biswal, PhD, DABR||Rutgers University, New Jersey, USA|
|Larry Bodgi, PhD||American University of Beirut Medical Centre, Lebanon|
|Marek Brzezinski, DSc||Centre of Molecular and Macromolecular Studies of the Polish Academy of Sciences, Poland|
|Calogero Casà, MD||Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy|
|Mustafa Cengiz, MD||Hacettepe University, Turkey|
|Pierre-Olivier Champagne, MD, PhD||Laval University, Canada|
|Kanchan Chauhan, PhD||Universidad Nacional Autónoma de México, CNyN-UNAM, Mexico|
|Daici Chen, PhD||Sixth Affiliated Hospital of Sun Yat-sen University|
|Lydia W. T. Cheung, PhD||The University of Hong Kong, China|
|Meer M. Chisthi, MS||Government Medical College, Trivandrum, India|
|Hua-Sheng Chiu, PhD||Baylor College of Medicine, USA|
|Ashish P. Chugh, MBBS, MS, MCh||Dr. D. Y. Patil Medical College and Hospital, India|
|Michael D. Chuong, MD||Baptist Health South Florida, Miami Cancer Institute, Florida, USA|
|Selma Corovic, PhD||University of Ljubljana, Slovenia|
|Matteo Costacurta, MD, PhD||Blood Cancer Therapeutics Laboratory, Monash University, Australia|
|Abhijeet P. Deshmukh, PhD||The University of Texas MD Anderson Cancer Centre, USA|
|Ravindra Deshpande, PhD||Wake Forest School of Medicine, USA|
|John DeSisto, PhD||University of Colorado, USA|
|Gagan Dhawan, PhD||University of Delhi, India|
|Liqin Du, PhD||Texas State University, USA|
|Hagar Elghaaawy, MD, PhD||Ain Shams University, Egypt|
|Soraya Emamgholizadeh Minaei, PhD||Urmia University of Medical Sciences, Iran|
|Zeenat Farooq, PhD||University of Illinois at Chicago, USA|
|Brigida d. Ferreira, PhD||Universidade de Lisboa, Portugal|
|Bruno Fionda, MD||Saint Camillus International University of Health and Medical Sciences, Italy|
|Roberto Giovannoni, PhD||University of Pisa, Italy|
|Gilar Gorji-Bahri, PhD||Shahid Beheshti University of Medical Sciences, Iran|
|Alessandro Granito, PhD||University of Bologna, Italy|
|Fabiana Gregucci, MD||Miulli General Regional Hospital, Italy|
|Andrea E. Guerini, MD||University of Brescia, Italy|
|Nitish Gulve, PhD||Ciscovery Bio Inc., Philadelphia, USA|
|Gamze Guney Eskiler, PhD||Sakarya University, Turkey|
|Marija Habijan, MS||Ghent University, Belgium|
|Shaghayegh Haghjoo Javanmard, MD, PhD||Isfahan University of Medical Sciences, Iran|
|A. Reza Haghpanah, MD||University of Medical Sciences, Shiraz, Iran|
|Nemany Hanafy, PhD||Kafrelsheikh University, Egypt|
|Mahmud Hasan, PhD||John Hopkins University of Medicine, USA|
|Wen Chien Hsi, PhD||University of Florida, USA|
|Chia-Hsien Hsu, PhD||Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Taiwan|
|Yingbo Huang, PhD||University of Minnesota, USA|
|Luis Exequiel Ibarra, PhD||Universidad Nacional de Río Cuarto, Argentina|
|Yasuhito Iwao, MD, PhD||Ohta Nishinouchi Hospital, Japan|
|Jaime Jacqueline Jayaplan, PhD||Universiti Malaya, Malaysia|
|Ameneh Jafari, PhD||Shahid Beheshti University of Medical Sciences, Tehran, Iran|
|Saket Jain, PhD||University of California San Francisco, USA|
|Luis Felipe Jave-Suarez, PhD||Instituto Mexicano Del Seguro Social, Mexico|
|Sheeba Jenifer Sujit, PhD||MD Anderson Cancer Center, USA|
|Keun-Yeong Jeong, PhD||Metimedi pharmaceuticals, South Korea|
|Erkan Kahraman, PhD||Ege University, Turkey|
|Ferda Kaleagasioglu, PhD||Istinye University, Turkey|
|Vaishali Kapoor, PhD||Washington University in St. Louis School of Medicine, USA|
|Atsuto Katano, PhD||The University of Tokyo Hospital, Japan|
|Muhammad Khalis Abdul Karim, PhD||Universiti Putra Malaysia, Malaysia|
|Ashok Kumar, PhD||All India Institute of Medical Sciences, India|
|Guiseppe La Rocca, PhD||Policlinico A. Gemelli, Roma, Italy|
|Dennis Larsson, PhD||Sahlgrenska University Hospital, Sweden|
|Shirley Lewis, MD, DNB, FRCR||Kasturba Medical College, India|
|Bingchen Li, PhD||Dana-Farber Cancer Institute/Harvard Medical School, USA|
|Chia-Yang Li, PhD||Kaohsiung Medical University, Taiwan|
|Mengshi Li, PhD||The University of Iowa, USA|
|Xiaodong Li, PhD||The Third Affiliated Hospital of Soochow University, China|
|Yiran Li, MD, PhD||Shanghai Tongji University, China|
|Shu-Fu Lin, MD||New Taipei Municipal TuCheng Hospital, Taiwan|
|Sanxiong Liu, PhD||NYU Langone Health, USA|
|Wenying Lu, PhD||University of Tasmania, Australia|
|Jun Lyu, MD, PhD||The First Affiliated Hospital of Jinan University, China|
|Zhongliang Ma, PhD||Shanghai University, China|
|Manish Devendra Mair, MS||John Hunter Hospital, Australia|
|Paramita Mandal, PhD||The University of Burdwan, India|
|Tessho Maruyama, PhD||University of the Ryukyus, Okinawa, Japan|
|Marwa Matboli, MD||Ain Shams Faculty of Medicine, Egypt|
|J. Michael Mathis, PhD||University of North Texas Health Science Center, USA|
|Abid Mattoo, PhD||Ultragenyx Pharmaceuticals, USA|
|Stephanie May, PhD||The Beatson Institute for Cancer Research, Glasgow, UK|
|Fiona McDonald, PhD||University of Otago, New Zealand|
|Nileshkumar Meghani, PhD||Inimmune Corp, USA|
|Pallavi Mehta, MD||Rajiv Gandhi Cancer Institute and Research Center, India|
|Bradley Mills, PhD||University of Rochester Medical Center, USA|
|Wafaa M Rashed, PhD||Children's Cancer Hospital, Egypt|
|Jitender Monga, MPharm, PhD||Henry Ford Health System, USA|
|Amr Muhammed, PhD||Sohag University, Egypt|
|Kumuraswamy Naidu Chitrala, PhD||Fels cancer institute for Personalized Medicine, USA|
|Lui Ng, PhD||Hong Kong University, Hong Kong, China|
|Saumya Nigam, PhD||Michigan State University, USA|
|Joseph Norris, MSc, MRCS, FESSR||University College London (UCL), UK|
|Livesey D. Olerile, PhD||DDT College of Medicine, Botswana|
|Mohamed M. Omran, PhD||Helwan University, Egypt|
|Aytug Onan, PhD||Izmir Katip Celebi University, Turkey|
|Chunlin Ou, PhD||Xiangya Hospital, Central South University, China|
|P. S. Suresh, PhD||National Institute of Technology, Calicut, India|
|Rahul Pal, PhD||Massachusetts General Hospital, Boston, USA|
|Ashok Palaniappan, PhD||SASTRA Deemed University, India|
|Antonio Palumbo Júnior, PhD||Federal University of Rio de Janeiro, Brazil|
|Arthur Paredes Gatti, MD||UNIFESP / ICESP, Brazil|
|Jiyeon Park, PhD||University of Florida College of Medicine, USA|
|Rajiv Pathak, PhD||Albert Einstein College of Medicine, USA|
|Maciej Pietrzak, PhD||The Ohio State University, USA|
|Veselin Popov, MD, PhD||Medical University Plovdiv, Bulgaria|
|Phillip Prior, PhD||Medical College of Wisconsin, USA|
|Chamindie Punyadeera, PhD||Griffith Institute for Drug Discovery|
|Wanqiong Qiao, PhD||Stanford University, USA|
|Laleh Rafiee, PhD||Isfahan University of Medical Sciences, Iran|
|Janaki Ramaiah, PhD||Koneru Lakshmaiah Education Foundation, India|
|Subhransu Sahoo, PhD||University of Texas Southwestern Medical Center, USA|
|Abbas Salihi, PhD||Salahaddin University, Iraq|
|Samson Mathews Samuel, M.Phil, PhD||Weill Cornell Medicine, Qatar|
|Rahul Sanawar, PhD||Albert Einstein College of Medicine, USA|
|Rahul Sankrityayan Kanumuri, PhD||Indiana University-Purdue University Indianapolis, USA|
|Sabrina Sarker, PhD||Technical University of Munich, Germany|
|Yasemin Saygideger, MD, PhD||Cukurova University, Turkey|
|Deepika Sharma, PhD||Institite of Nano Science and Technology, India|
|May Shawki, PhD||Ain Shams University, Egypt|
|Chun-Chien Shieh, PhD||The University of Sydney, Australia|
|Valentina Siino, PhD||Acrivon Therepeutics, USA|
|Manpreet Singh, PhD||University of Maryland, Baltimore, USA|
|Simon John Christoph Soerensen, MD||Stanford University, USA|
|Jafar Soleymani, PhD||Tabriz University of Medical Sciences, Iran|
|Sourabh Soni, PhD||Brigham and Women's Hospital, Harvard Medical School, Boston, USA|
|Govindarajan Srimathveeravalli, PhD||Memorial Sloan Kettering Cancer Center, New York, USA|
|Yilun Sun, PhD||National Cancer Institute, NIH, USA|
|Yasin Tuluce, PhD||Van Yüzüncü Yil Üniversity, Turkey|
|Ram Babu Undi, PhD||The University of Oklahoma Health Sciences Center, USA|
|Eduardo López Urrutia, PhD||Universidad Nacional Autónoma de México Facultad de Estudios Superiores Iztacala, Mexico|
|Pietro Valerio Foti, MD||University Hospital Policlinico “G. Rodolico-San Marco", Italy|
|Antti Vanhanen, PhD||Tampere University Hospital, Finland|
|Miguel Ángel Velázquez Flores, DSc||Instituto Mexicano Del Seguro Social, Mexico|
|Ganesh Venkatraman, PhD||Sri Ramachandra Institute of Higher Education and Resesarch|
|Domenico Viggiano, MD||University Hospital Careggi, Italy|
|Austin W.T Chiang, PhD||University of California, USA|
|Chunhao Wang, PhD||Duke University Medical Center, Durham, North Carolina, USA|
|Ujjwala M.Warawdekar, PhD||Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, India|
|Christopher Wasson, PhD||University of Leeds, United Kingdom|
|Ching-Feng Weng, PhD||University of Maryland at Baltimore, USA|
|Jiajia Xi, PhD||Lerner Research Institute, Cleveland Clinic, USA|
|Feng Xu, MD, PhD||Shantou University Medical College, China|
|Yingkun Xu, PhD||Chongqing Medical University, China|
|Abdullah Yalcin, PhD||Bursa Uludag University, Bursa, Turkey|
|Wenhui Yi, PhD||Xi’an Jiaotong University, China|
|Zeki Yumuk, MD, PhD||Kocaeli University, Turkey|
|Chao Zhang, PhD, MA, MPH||General Dynamics Information Technology, Inc., USA|
|Yue Zou, PhD||Weill Cornell Medical College, USA|
Before you submit your research, please make sure your paper meets the below criteria:
Your paper is an original work and has not been published or currently under review with another journal.
Only authors that have contributed to the work are added. Please see ICMJE's guidelines "Defining Roles of Authors and Contributors".
Your work meets all Research Ethics and Reporting Standards. Many study types require a workflow as a figure and/or a completed checklist uploaded as a supplementary file for peer review. Visit here to see if your study type requires a workflow and/or checklist.
Your figures are of acceptable quality and uploaded as separate files. Line art should be 900-1200 DPI, images 300 DPI. Images should be minimally processed to uphold their original integrity. More figure information here.
Your references are formatted correctly and numbered as they appear in the text. Please visit here for reference style.
Data and complete methods should be made available so that others may replicate your study. If applicable, please see here for more information and data repositories.
Please download and include the following forms when submitting your paper (some papers may require multiple forms).
For life science research papers, please download this Data Presentation Checklist and submit it with your paper.
For clinical papers, please download and attach the following Ethics Declaration Form and submit it along with your paper.
For animal research papers, please download the following ARRIVE Compliance Form and submit it along with your paper.
Authors must have an understanding and agreement to pay any applicable article processing charges (APCs).
Only manuscripts of sufficient quality that meet the aims & scope of the journal will be reviewed.
Full guidelines are below. Submissions that don't adhere to these instructions will be returned prior to peer review.
Once your manuscript meets all criteria above and below, you can submit it through our online submission system here.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing,
and Publication of Scholarly Work in Medical Journals formulated by the International Committee of
Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site
https://mc.manuscriptcentral.com/TCRT to upload your manuscript. Please note that manuscripts not
conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Please also be sure to look over the submission checklist here before submitting.
SAGE Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.
Only manuscripts of sufficient quality that meet the aims and scope of Technology in Cancer Research &
Treatment will be reviewed.
As part of the submission process, you will be required to warrant that you are submitting your original
work, that you have the rights in the work, that you are submitting the work for first publication in the
Journal and that it is not being considered for publication elsewhere and has not already been published
elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of
any copyright works not owned by you.
Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.2.1 Original research articles
3.2.2 Review articles
3.2.3 Mini Review articles
3.2.4 Study Protocol articles
3.2.5 Opinion pieces
3.2.6 Letters to the Editor
3.2.7 Validation Studies
3.3 Writing your paper
3.3.1 Making your article discoverable
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
4.9 Research Data
- Publishing policies
5.1 Publication ethics
5.1.2 Prior publication
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.1.1 Title and Authors (On a separate title page)
6.1.2 Manuscript Preparation
6.2 Artwork, figures and other graphics
6.3 Supplemental material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
7.5 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Online publication
8.3 Promoting your article
- Further information
Technology in Cancer Research & Treatment is an open access, peer reviewed journal. Each article
accepted by peer review is made freely available online immediately upon publication, is published
under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the
journal are covered by the collection of article processing charges which are paid by the funder,
institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge
(APC) is payable. This APC covers the cost of publication and ensures that your article will be freely
available online in perpetuity under a Creative Commons license.
The article processing charge (APC) is currently $2,400 USD (+VAT where applicable*).
Before submitting your manuscript to Technology in Cancer Research & Treatment, please
ensure you have read the Aims & Scope.
For studies that only contain bioinformatics, computational analysis, or predictions made using public databases, the journal only considers those manuscripts which include robust external validation using an independent cohort or biological validation in vitro or in vivo and have potential clinical applications.
Original, in-depth, research articles must follow the Aims & Scope of TCRT with emphasis on prevention, diagnosis, treatment, and monitoring of cancer. Research articles must have the potential for clinical application. For bioinformatics studies, external clinical validation is expected. For in vitro studies, a molecular mechanism should be presented. TCRT does not impose word or figure limits, but does reserve the right to ask for manuscripts to be edited and/or shortened.
Review Articles should report on the existing state of understanding in a specific
research area and/or topic. TCRT does not impose word or figure limits but does
reserve the right to ask for manuscripts to be edited and/or shortened.
Mini Reviews are articles that focus on recent significant advances in fields that are within the scope of TCRT. They are clear, succinct summaries that provide an up-to-date overview of progress, new developments, and/or emerging concepts in a specific field. Mini Reviews must provide clinical context and discussion of challenges and potential future developments. Mini Reviews should be approximately 2000 words. The abstract should not exceed 350 words and should be structure with a background, main body, and short conclusion. Mini Reviews should not include unpublished material or personal communications.
Study Protocols are articles that describe the design of planned or ongoing research. This includes study design for observational, qualitative, exploratory studies, experimental studies, and systematic reviews. Study designs for clinical trials are especially encouraged. TCRT endorses the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement, which provides important guidance on drafting protocols, and the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, which provide a 17-item checklist for preparing systematic review and meta-analysis protocols. Authors are encourage to follow these guidelines when preparing a study protocol manuscript. For more information on preparing a Study Protocol for submission, refer to this document.
Opinion Pieces should not exceed four printed pages. Papers in this section should
present a new vision or perspective of recent developments. They may also critically
address recent publications from any journal. In the latter case, the criticized authors
will be given a chance to write a prompt response. Articles in this section should address
unsolved controversies arising in current research.
Letters to the Editor should consist of one or two paragraphs totaling no more than 500 words,
no abstract, no subheadings and fewer than 8 references (one author, et al., no titles). If an
abstract is included, it will automatically be made the first paragraph. Letters should not include
figures or research material. Letters to the editor are not charged an APC.
A letter to the editor is a brief communication that addresses the contents of a published article.
Its purpose is to make corrections, provide alternative viewpoints, or offer counter-arguments. Avoid
logical fallacies and ad hominem attacks. Letters to the editor must be written in a professional tone
and include references to support all claims if appropriate.
Validation or Replication studies can be submitted to the journal. These should be carried out to validate that a scientific finding is accurate, reliable and reproducible. These may be written in the style of a Brief Communication or a Research Paper with a brief introduction.
The SAGE Author Gateway has some general advice and on how to get published, plus links to
When writing up your paper, think about how you can make it discoverable. The title,
keywords and abstract are key to ensuring readers find your article through search
engines such as Google. For information and guidance on how best to title your article,
write your abstract and select your keywords, have a look at this page on the Gateway:
How to Help Readers Find Your Article Online
Technology in Cancer Research & Treatment offers transparent peer review as a choice for authors, where the reviews at each stage, author responses and editor’s decision letters will be publicly available on the ScholarOne Transparent Peer Review platform and linked to from the published article should the article be accepted. Authors have the opportunity to opt-out during submission. Reviewers are encouraged to sign their reviews but their comments will be published anonymously should they choose not to do so.
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Technology in Cancer Research & Treatment utilizes a double-blind peer review process in which the reviewer and authors’ names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible while maintaining rigor. Reviewers make comments to the author and recommendations to the Managing Editor who then makes the final decision.
**When uploading your manuscript, please make sure no identifying information is included
in the main document, including in the acknowledgments, funding and conflict of interest
statements. If any of these statements contain identifying information, please put the
statements on the title page.
Technology in Cancer Research & Treatment is committed to delivering high quality, fast peer review
for your paper, and as such has partnered with Publons. Publons is a third party service
that seeks to track, verify and give credit for peer review. Reviewers for Technology in Cancer
Research & Treatment can opt in to Publons in order to claim their reviews or have them
automatically verified and added to their reviewer profile. Reviewers claiming credit for their
review will be associated with the relevant journal, but the article name, reviewer’s decision and
the content of their review is not published on the site. For more information visit the Publons
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for
possible publication in the journal. In these cases, the peer review process will be managed by
alternative members of the Board and the submitting Editor/Board member will have no
involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing
authors. Those submitting papers should carefully check that all those whose work contributed
to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all
(i) Made a substantial contribution to the concept or design of the work; or acquisition,
analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public
responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have
participated sufficiently in the work to take public responsibility for appropriate portions of the
When a large, multicentre group has conducted the work, the group should identify the
individuals who accept direct responsibility for the manuscript. These individuals should fully
meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone
does not constitute authorship, although all contributors who do not meet the criteria for
authorship should be listed in the Acknowledgments section. Please refer to the International
Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.
4.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
4.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Please supply any personal acknowledgments separately to the main text to facilitate anonymous peer review.
Technology in Cancer Research & Treatment requires all authors to acknowledge their funding in
a consistent fashion under a separate heading. Please visit the Funding Acknowledgements
page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in
the event of funding, or state: This research received no specific grant from any funding
agency in the public, commercial, or not-for-profit sectors.
It is the policy of Technology in Cancer Research & Treatment to require a declaration of
conflicting interests from all authors enabling a statement to be carried within the paginated
pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of
your manuscript, after any acknowledgments and prior to the references. If no conflict exists,
please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical
Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers
reporting animal and/or human studies must state in the methods section that the relevant
Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure
that you have provided the full name and institution of the review committee, in addition to the
For research articles, authors are also required to state in the methods section whether participants
rovided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the
manuscript text. A statement is required regarding whether written informed consent for patient information
and images to be published was provided by the patient(s) or a legally authorized representative. Please
do not submit the patient’s actual written informed consent with your article, as this in itself breaches the
patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained
written informed consent but the written consent itself should be held by the authors/investigators
themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your
submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
Technology in Cancer Research & Treatment conforms to the ICMJE requirement that clinical
trials are registered in a WHO-approved public trials registry at or before the time of first patient
enrolment as a condition of consideration for publication. The trial registry name and URL, and
registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type
of study. For example, all randomized controlled trials submitted for publication should include
a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should
be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses
should include the completed PRISMA flow chart as a cited figure and the completed
PRISMA checklist should be uploaded with your submission as a supplementary file. Observational studies in epidemiology (cohor, case-control, cross-sectional studies) should include the completed STROBE checklist as a supplementary file with your submission. Animal studies should have the completed ARRIVES checklist uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the SAGE Research Data policy pages
Subject to appropriate ethical and legal considerations, authors are encouraged to:
- share your research data in a relevant public data repository
- include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
- cite this data in your research
SAGE is committed to upholding the integrity of the academic record. We encourage authors to
refer to the Committee on Publication Ethics’ International Standards for Authors and view the
Publication Ethics page on the SAGE Author Gateway.
Technology in Cancer Research & Treatment and SAGE take issues of copyright infringement,
plagiarism or other breaches of best practice in publication very seriously. We seek to protect
the rights of our authors and we always investigate claims of plagiarism or misuse of published
articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted
articles may be checked with duplication-checking software. Where an article, for example, is
found to have plagiarized other work or included third-party copyright material without
permission or with insufficient acknowledgement, or where the authorship of the article is
contested, we reserve the right to take action including, but not limited to: publishing an
erratum or corrigendum (correction); retracting the article; taking up the matter with the head
of department or dean of the author's institution and/or relevant academic bodies or societies;
or taking appropriate legal action.
If any material has been previously published, it is not generally acceptable for publication in a SAGE
journal. However, there are certain circumstances where previously published material can be
considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in
doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s
Publishing Agreement. Technology in Cancer Research & Treatment publishes manuscripts
under Creative Commons licenses. The standard license for the journal is Creative Commons by
Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without
permission as long as the work is properly referenced and the use is non-commercial. For more
information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder
mandates, made at the author’s request.
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files
are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for
left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point.
TCRT follows IUPAC-IUB nomenclature. Word and (La)Tex templates are available on the
Manuscript Submission Guidelines page of our Author Gateway.
- Title should be in upper and lower case (Do not use all UPPERcase)
- Author first name (or initials), middle initial, and last name (surname, family name)
- and degree(s)
- Affiliations: use 1, 2, etc. after the degree
- Put an * after the name of the corresponding author
Please add line and page numbers to your document.
The abstract should be 250-300 words and should reflect the results. Describe the
purpose of the study and briefly explain how the study was performed. Summarize the
most important observations and their significance. Do not use abbreviations in the
Following the abstract, please list 5-6 keywords for indexing the article. Keywords, along
with the abstract and title, are central to ensuring that readers can search for and find
your article online. For this reason, to aid in search-ability, words in the title should not
be used as keywords. For keyword suggestions, please visit the National Library of
Medicine’s Medical Subject Headings (MeSH®) website.
Please include a list of all abbreviations used in the manuscript. These should be listed
in alphabetical order. (Example: MRI, Magnetic Resonance Imaging; RT, Radiation
Provide background that allows readers outside the discipline to understand the significance
of the study. Include a brief review of important literature in the relevant field.
Materials and Methods
Please do not use numbering or subheadings. Describe in detail any new methods or
protocols used, in order that other investigators can replicate the study. Older, better known
methods may be cited in references but should be described enough that the
reader may understand the method. Manufacturer names of reagents and equipment used should be included.
For immunohistochemistry, blots, and gels the following should be included: catalog numbers, manufacturer names, and dilutions of antibodies. While the journal does not require use of RRIDs, it is recommended. Raw data for immunohistochemistry, blots, gels, cell assays are recommended to be included at submission and can be uploaded as the Research Data file type.
Specific Reporting Guidelines
Medical research involving human subjects must be conducted according to the World
Medical Association Declaration of Helsinki. Submitted manuscripts should conform to
the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of
Scholarly Work in Medical Journals, and all papers reporting animal and/or human
studies must state in the methods section that the relevant Ethics Committee or
Institutional Review Board provided (or waived) approval. Please ensure that you have
provided the full name and institution of the review committee, the approval number, and date of approval. For research articles, authors are also required to state in the
methods section whether participants provided informed consent and whether the
consent was written or verbal.
Human Subject Research
If using human subjects, the title page must include ethics statements that
- The name of the approving institutional review board (IRB) or equivalent
committees, the approval number, and the date of approval. A copy of the ethics form should be included as a supplmental file with the submission. If approval was not obtained, a detailed statement explaining the reason is required. A version of the statement blinded for peer review should be included in the materials and methods section.
- Nature of Informed consent – oral or written. If oral, how the consent
was documented should be stated in the manuscript. If written consent
was not obtained, the reasons should be stated in the materials and methods section of the manuscript.
The methods section of the manuscript reporting animal research must include
ethics statements that specify the relevant ethics committee approving the
research, the approval number, and date of approval. A copy of the ethics form should be included as a supplmental file with the submission. If ethical approval was not required,
reasons should be stated in the manuscript. Relevant details to minimize
suffering of the animal should be mentioned.
Cell Line Research
The methods section should state the origin of the cell lines. In cases of established
cell lines, in addition to origin, the commercial source should be given. If
previously unpublished new cell lines were used, the source should be
For prospective studies, the type of study needs to be indicated in the abstract and materials and methods section. Studies must be reported according to the relevant Equator network guideline. The materials and methods section should include a statement that the study has followed the relevant guideline and the guideline should be cited. The completed relevant reporting checklist must be included as a supplemental file at submission. For randomised trials, the CONSORT statement must be followed. Clinical trials must be registered with a publicly accessible database prior to submission. The registration number must be included at the end of the abstract and in the materials and methods section.
For retrospective studies, the type of study needs to be indicated in the abstract and materials and methods section. Studies must be reported according to the relevant Equator network guideline. The materials and methods section should include a statement that the study has followed the relevant guideline and the guideline should be cited. The completed relevant reporting checklist must be included as a supplemental file at submission.
For systematic reviews and meta-analyses, the study type needs to be indicated in the title, abstract, and materials and methods. Studies must be reported according to the relevant Equator network guideline. The PRISMA flow diagram should be included as a figure. The study should be registered with PROSPERO and the registration should be included in the submission.
Explain how the results relate to the premise of the study especially in relation to
previous related studies and how the present study results might have potential in
directing future research.
Describe the interpretation of the data.
Avoid overemphasizing the conclusion.
Conflict of Interests Statement
At the end of the manuscript, before the Acknowledgements section, statements
related to conflicts of interest must appear.
List the names of the individuals along with the contributors who have participated in
some capacity but cannot be qualified as authors.
Disclose if any funds were received to conduct the research.
Technology in Cancer Research & Treatment adheres to AMA reference style. In the
references section (i.e., bibliography), please list references in the same order as they
were cited in the manuscript. When a website is cited as a reference, provide the date
that the website was last accessed.
Unpublished data and personal correspondence may be cited as references within the
text itself and are not to be included in the list of references. Authors are fully
responsible for the accuracy of references used, and all text quoted. Manuscripts
submitted in any other format may delay the publication of your article.
All figures and illustrations should contain clean and clear graphics, and must be submitted
electronically in their original format (e.g., png, jpeg, tif).
Line art must have a resolution of at least 900 dpi (dots per inch). Electronic photographs,
radiographs, CT scans, MRIs, all medical imaging, and all scanned images must have a resolution
of at least 300 dpi. If fonts are used in the artwork, they must be embedded in the files. Color
images must be created/scanned and saved and submitted as CMYK files. Please note that
artwork downloaded from the internet (JPEG or GIF files) cannot be used.
Ensure that fonts are clear and easy to read should the figures be resized to a 1-column or 2-
column format during the layout process of publication. Please use the following guidelines
when preparing your image files:
For graphics reprinted from another source, provide written permission for reproduction from
the copyright owner. Include full credit in the manuscript’s text, figure legends, and/or in the
acknowledgment section, as appropriate.
Embed all images in the manuscript and submit separate files for each image in the original
format it was created (e.g., png, jpeg, tiff).
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please
visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
If your manuscript is in .docx format and contains equations, make sure the equations are
editable. Equations must be placed in brackets [ ].
Tables should have a concise title and should not occupy more than one printed page. Indicate
in red where to place the Figures and Tables. Create tables in Word format within the
Use Arabic numerals to name tables (e.g. Table 1). Cite tables in the text in consecutive order.
For each table, provide a table heading that clearly and concisely explains the content of the
table. Indicate table footnotes with lower-case letters in superscript font. Place the information
for the footnote beneath the body of the table.
If a table will be submitted as a separate document, the filename should contain the surname of
the first author and match its label in the manuscript (e.g., SMITH Table 1).
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.)
alongside the full-text of the article. For more information please refer to our guidelines on submitting
Technology in Cancer Research & Treatment adheres to the AMA reference style. Please review
the guidelines on AMA to ensure your manuscript conforms to this reference style.
If you use EndNote to manage references, you can download the AMA output file here.
Authors seeking assistance with English language editing, translation, or figure and manuscript
formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit
SAGE Language Services on our Journal Author Gateway for further information.
Technology in Cancer Research & Treatment is hosted on SAGE Track, a web-based online
submission and peer review system powered by ScholarOne™ Manuscripts. Visit
https://mc.manuscriptcentral.com/TCRT to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to
create a new one. If you have reviewed or authored for the journal in the past year it is likely
that you will have had an account created. For further guidance on submitting your manuscript
online please visit ScholarOne Online Help.
Please supply a title, short title, an abstract and keywords to accompany your article. The title,
keywords and abstract are key to ensuring readers find your article online through online search
engines such as Google. Please refer to the information and guidance on how best to title your
article, write your abstract and select your keywords by visiting the SAGE Journal Author
Gateway for guidelines on How to Help Readers Find Your Article Online.
Provide full contact details for the corresponding author including email, mailing address and
telephone numbers. Academic affiliations are required for all co-authors. These details should
be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the
submission system and identify who is to be the corresponding author. These details must
match what appears on your manuscript. At this stage please ensure you have included all the
required statements and declarations and uploaded any additional supplementary files
(including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a
supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique
and persistent digital identifier that distinguishes researchers from every other researcher, even
those who share the same name, and, through integration in key research workflows such as
manuscript and grant submission, supports automated linkages between researchers and their
professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this
journal. If you already have an ORCID iD you will be asked to associate that to your submission
during the online submission process. We also strongly encourage all co-authors to link their ORCID
ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when
prompted, sign in to your ORCID account and our systems are automatically updated. Your ORCID iD
will become part of your accepted publication’s metadata, making your work attributable to you and
only you. Your ORCID iD is published with your article so that fellow researchers reading your work
can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission
system and identify who is to be the corresponding author. These details must match what appears on
your manuscript. The affiliation listed on the manuscript should be the institution where the research was
conducted. If an author has moved to a new institution since completing the research, the new affiliation
can be included in a manuscript note at the end of the paper. At this stage please ensure you have
included all the required statements and declarations and uploaded any additional supplementary files
(including reporting guidelines where relevant).
Authors are responsible for obtaining permission from copyright holders for reproducing any
illustrations, tables, figures or lengthy quotations previously published elsewhere. For further
information including guidance on fair dealing for criticism and review, please visit our
Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the
contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production,
the corresponding author will be asked to pay the article processing charge (APC) via a payment link.
Once the APC has been processed, your article will be prepared for publication and can appear online
within an average of 30 days. Please note that no production work will occur on your paper until the
APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to
publication. With no page count constraints, your article will be published online in a fully
citable form with a DOI number as soon as it has completed the production process. At this time
it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is
as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help
you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the Manuscript Submission
process should be sent to the Technology in Cancer Research & Treatment Editorial Office | firstname.lastname@example.org